scholarly journals Don’t Miss Lupus

2021 ◽  
Author(s):  
Stephen Soloway

Chapter for Lupus Book Systemic lupus erythematosus is a well-recognized multi-system disease. Hallmarks of the disorder include the prevalence of antinuclear antibodies (ANA) and double stranded antibodies (DNA). The disease often presents with lupus rashes and/or arthritis or arthralgias. Lupus is “the great imitator,” as no organ system is excluded, when diagnosing and treating a lupus patient. While lupus remains evasive in novel therapies with true benefit; one issue has been consistent, in that the preponderance of the evidence thus far, leads to B cell dysfunction. More recently Belimumab was indicated for use in lupus patients. This is a BLyS-Specific inhibitor (B lymphocyte stimulator) medication. At this time, I would like to focus on lupus in a manner that you are not used to hearing. Typically, any practitioner who approaches a patient with a plethora of symptoms, would order blood tests, and conclude a diagnosis of lupus. In this chapter, I will point out and focus on the need to think “outside the box” and perhaps consider lupus as simply one of various other scenarios.

2009 ◽  
Vol 60 (11) ◽  
pp. 3400-3409 ◽  
Author(s):  
Sandy D. Hong ◽  
Andreas Reiff ◽  
Hai-Tao Yang ◽  
Thi-Sau Migone ◽  
Christopher D. Ward ◽  
...  

Lupus ◽  
2018 ◽  
Vol 27 (12) ◽  
pp. 1926-1935 ◽  
Author(s):  
M Prete ◽  
P Leone ◽  
M A Frassanito ◽  
V Desantis ◽  
C Marasco ◽  
...  

Belimumab, a specific inhibitor of the soluble B lymphocyte stimulator (BlyS), is the first biological drug approved by the United States Food and Drug Administration for the treatment of patients with active systemic lupus erythematosus (SLE) refractory to standard therapy. Given that an imbalance between regulatory T cells (Treg) and interleukin (IL)-17A-secreting T cells (Th17) has been reported in various autoimmune disorders, we assessed the frequency of both Treg and Th17 peripheral blood populations before and after belimumab administration in 20 patients with active SLE refractory to standard therapy. After six months of treatment, the mean SELENA-SLEDAI score as well as the mean anti-double-stranded DNA antibody titers were significantly decreased. In addition, we observed a significant increase in Treg percentages and a parallel, significant decrease in Th17 percentages, accompanied by significantly reduced serum levels of IL-21. In vitro studies showed that Treg purified from belimumab-treated patients were fully functional and displayed a suppressor function similar to that of Treg purified from healthy donors. Belimumab can restore Treg/Th17 balance in SLE patients with uncontrolled disease activity, and this results in decreased flare rate and reduced glucocorticoid dosage.


2003 ◽  
Vol 48 (12) ◽  
pp. 3475-3486 ◽  
Author(s):  
William Stohl ◽  
Samy Metyas ◽  
Soon-Min Tan ◽  
Gurtej S. Cheema ◽  
Bonifacia Oamar ◽  
...  

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 577.1-577 ◽  
Author(s):  
N.S. Fajardo-Robledo ◽  
V. Diaz-Rizo ◽  
E.E. Perez-Guerrero ◽  
D. Bonilla-Lara ◽  
J.M. Saldaña-Anguiano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document